Lenz Therapeutics initiated with an Outperform at Raymond James
PremiumThe FlyLenz Therapeutics initiated with an Outperform at Raymond James
1M ago
Lenz Therapeutics files to sell 1.58M shares of common stock for holders
Premium
The Fly
Lenz Therapeutics files to sell 1.58M shares of common stock for holders
2M ago
Lenz Therapeutics reports Q2 EPS (40c), consensus (48c)
Premium
The Fly
Lenz Therapeutics reports Q2 EPS (40c), consensus (48c)
3M ago
Lenz Therapeutics announces $30M investment from Ridgeback Capital
PremiumThe FlyLenz Therapeutics announces $30M investment from Ridgeback Capital
4M ago
Lenz Therapeutics management to meet with Piper Sandler
Premium
The Fly
Lenz Therapeutics management to meet with Piper Sandler
6M ago
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
Premium
Company Announcements
Lenz Therapeutics’ Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape
6M ago
Lenz Therapeutics initiated with a Buy at Citi
PremiumThe FlyLenz Therapeutics initiated with a Buy at Citi
7M ago
LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
Premium
Market News
LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
7M ago
Lenz Therapeutics announces results from Phase 3 CLARITY study
Premium
The Fly
Lenz Therapeutics announces results from Phase 3 CLARITY study
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100